Brokerage Firm Rating on Puma Biotechnology Inc (PBYI)

Puma Biotechnology Inc (PBYI) : 3 brokerage houses believe that Puma Biotechnology Inc (PBYI) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Puma Biotechnology Inc (PBYI). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 6 Wall Street Analysts endorse the stock as a Buy with a rating of 2.

Puma Biotechnology Inc (PBYI) : 3 investment research analysts covering Puma Biotechnology Inc (PBYI) have an average price target of $55.33 for the near short term. The highest target price given by the Brokerage Firm to the stock is $70 and the lowest target is $36 for the short term. Analysts expect the variance to be within $17.47 of the average price.


For the current week, the company shares have a recommendation consensus of Buy. Puma Biotechnology Inc (NYSE:PBYI): The stock opened at $46.14 on Thursday but the bulls could not build on the opening and the stock topped out at $46.48 for the day. The stock traded down to $44.73 during the day, due to lack of any buying support eventually closed down at $45.78 with a loss of -0.37% for the day. The stock had closed at $45.95 on the previous day. The total traded volume was 325,810 shares.

In a related news,The officer (SR VP, CLINICAL RESEARCH & DEV) of Puma Biotechnology, Inc., Bryce Richard Paul sold 3,000 shares at $110.03 on July 6, 2015. The Insider selling transaction had a total value worth of $330,090. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *